Treatment of hidradenitis suppurativa using JAK inhibitors
The present application provides methods of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and/or JAK2, or a pharmaceutically acceptable salt thereof.
1. A method of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which is:
4[3-(cyanomethyl)-3-(3′,5′-dimethyl-1H,1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the compound or salt is selective for JAK1 over JAK2, JAK3, and TYK2.
3. The method of claim 1 , wherein the compound is a pharmaceutically acceptable salt of 4[3-(cyanomethyl)-3-(3′,5′-dimethyl-1H,1H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide.
4. The method of claim 3 , wherein the salt is 4-[3-(cyanomethyl)-3-(3′,5′-dimethyl-1H, 1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide phosphoric acid salt.
5. The method of claim 1 , wherein the compound or salt is administered at a dosage of 15, 30, 60 or 90 mg on a free base basis.
6. The method of claim 1 , further comprising administering an additional therapeutic agent.
7. The method of claim 6 , wherein the additional therapeutic agent is an antibiotic, a retinoid, a corticosteroid, an anti-TNF-alpha agent, or an immunosuppressant.
8. The method of claim 7 , wherein the antibiotic is clindamycin, doxycycline, minocycline, trimethoprim-sulfamethoxazole, erythromycin, metronidazole, rifampin, moxifloxacin, dapsone, or a combination thereof.
9. The method of claim 7 , wherein the retinoid is etretinate, acitretin, or isotretinoin.
10. The method of claim 7 , wherein the corticosteroid is triamcinolone, dexamethasone, fluocinolone, cortisone, prednisone, prednisolone or flumetholone.
11. The method of claim 7 , wherein the anti-TNF-alpha agent is infliximab, etanercept, or adalimumab.
12. The method of claim 7 , wherein the immunosuppressant is methotrexate, cyclosporin A, mycophenolate mofetil, or mycophenolate sodium.
13. The method of claim 6 , wherein the additional therapeutic agent is finasteride, metformin, adapalene, or azelaic acid.
14. The method of claim 1 , wherein the administrating of the compound or salt is topical.
15. The method of claim 1 , wherein the administering of the compound or salt is oral.
16. The method of claim 1 , wherein the method results in a 10%, 20%, 30%, 40%, or 50% improvement in HiSCR (Hidradenitis Suppurativa Clinical Response).
17. The method of claim 1 , wherein the compound is 4-[3-(cyanomethyl)-3-(3′,5′-dimethyl-1H,1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide free base.